Return to Listing

10 result(s) for Lymphoma

PI Name Protocol # Title
Andy Chen IRB00008906 GO27834: A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of pinatuzumab vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and A Non Randomized phase Ib/II Evaluation of Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-cell Non- Hodgkin’s Lymphoma
Stephen Spurgeon IRB00010383 A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-Lag-3 (BMS-986016) in Relapsed or Refractory Chronic Lymphocytic Leukemia and Lymphomas
Richard Maziarz IRB00010941 A Multi-center Phase II Trial Randomizing Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls
Rachel Cook IRB00011076 A Phase I Dose Escalation with Two Disease Specific Expansions, Multicenter, Open-label, Safety, Pharmacokinetic and Pharmacodynamic Study of LOR-253 in Patients with Relapsed or Refractory Hematologic Malignancies
Stephen Spurgeon IRB00011311 A Phase 1/2 Proof-of-concept study of the combination of ACP-196 and ACP-319 in subjects with B-cell malignancies
Stephen Spurgeon IRB00011800 Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB → R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV→ R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB → LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV → LR)
Brandon Hayes-Lattin IRB00011894 Protocol CCTL019B2206: A multicenter study of apheresis collection of peripheral blood mononuclear cells (PBMC) in patients with CD19 expressing malignancies who could be eligible for a CTL019 clinical research trial
Richard Maziarz IRB00011943 CCTL019C2201 A Multicenter Trial to Determine the Efficacy and Safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Brandon Hayes-Lattin IRB00011960 Long Term Follow-Up of Patients Exposed to Lentiviral- Based CD19 directed CART Cell Therapy
Kim-Hien Dao STUDY00015363 WEAR in Oregon: Defining risks of blood cancer development in a cohort of older women with clonal hematopoiesis and TET2 mutations. (Women Engaged in Advancing health Research in Oregon is a prospective epidemiology study)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080